Profound Sinoatrial Arrest Associated with Ibrutinib

BACKGROUNDIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertensio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in oncological medicine 2017, Vol.2017, p.7304021-7304021
Hauptverfasser: Mathur, Kanupriya, Saini, Aditya, Ellenbogen, Kenneth A, Shepard, Richard K
Format: Report
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7304021
container_issue
container_start_page 7304021
container_title Case reports in oncological medicine
container_volume 2017
creator Mathur, Kanupriya
Saini, Aditya
Ellenbogen, Kenneth A
Shepard, Richard K
description BACKGROUNDIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertension in multiple studies. Other forms of cardiac toxicities have also been reported in isolated case reports. Bradycardia and asystole have not been associated with ibrutinib use in the past. CASE REPORTWe present a case of a 76-year-old female with no prior cardiac history, who initiated treatment with ibrutinib for relapsing mantle cell lymphoma and was noted to have symptomatic bradycardia, greater than 20 second long pauses on her cardiac monitor requiring placement of a permanent pacemaker. CONCLUSIONThis is the first case associating bradycardia and asystole with tyrosine kinase inhibitor use. Irreversible inhibition of certain cardioprotective tyrosine kinases has been a growing topic of research in oncology therapeutics.
doi_str_mv 10.1155/2017/7304021
format Report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1993009947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993009947</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_19930099473</originalsourceid><addsrcrecordid>eNqVi70OwiAYABk0sdFuPgCjS-0HbSGMjdHoZqJ7Q1saMQjKT3x9HXwBb7nlDqE1gS0hTVNSILzkFdRAyQxlFAQUjANboDyEO3xhlDHgGarP3k0u2RFftHUyei0Nbr1XIeI2BDdoGdWI3zre8Kn3KWqr-xWaT9IElf-8RJvD_ro7Fk_vXum7dg8dBmWMtMql0BEhKgAhal79kX4A2Nk9CQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>1993009947</pqid></control><display><type>report</type><title>Profound Sinoatrial Arrest Associated with Ibrutinib</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Mathur, Kanupriya ; Saini, Aditya ; Ellenbogen, Kenneth A ; Shepard, Richard K</creator><creatorcontrib>Mathur, Kanupriya ; Saini, Aditya ; Ellenbogen, Kenneth A ; Shepard, Richard K</creatorcontrib><description>BACKGROUNDIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertension in multiple studies. Other forms of cardiac toxicities have also been reported in isolated case reports. Bradycardia and asystole have not been associated with ibrutinib use in the past. CASE REPORTWe present a case of a 76-year-old female with no prior cardiac history, who initiated treatment with ibrutinib for relapsing mantle cell lymphoma and was noted to have symptomatic bradycardia, greater than 20 second long pauses on her cardiac monitor requiring placement of a permanent pacemaker. CONCLUSIONThis is the first case associating bradycardia and asystole with tyrosine kinase inhibitor use. Irreversible inhibition of certain cardioprotective tyrosine kinases has been a growing topic of research in oncology therapeutics.</description><identifier>ISSN: 2090-6706</identifier><identifier>DOI: 10.1155/2017/7304021</identifier><language>eng</language><ispartof>Case reports in oncological medicine, 2017, Vol.2017, p.7304021-7304021</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,864,4490,27925</link.rule.ids></links><search><creatorcontrib>Mathur, Kanupriya</creatorcontrib><creatorcontrib>Saini, Aditya</creatorcontrib><creatorcontrib>Ellenbogen, Kenneth A</creatorcontrib><creatorcontrib>Shepard, Richard K</creatorcontrib><title>Profound Sinoatrial Arrest Associated with Ibrutinib</title><title>Case reports in oncological medicine</title><description>BACKGROUNDIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertension in multiple studies. Other forms of cardiac toxicities have also been reported in isolated case reports. Bradycardia and asystole have not been associated with ibrutinib use in the past. CASE REPORTWe present a case of a 76-year-old female with no prior cardiac history, who initiated treatment with ibrutinib for relapsing mantle cell lymphoma and was noted to have symptomatic bradycardia, greater than 20 second long pauses on her cardiac monitor requiring placement of a permanent pacemaker. CONCLUSIONThis is the first case associating bradycardia and asystole with tyrosine kinase inhibitor use. Irreversible inhibition of certain cardioprotective tyrosine kinases has been a growing topic of research in oncology therapeutics.</description><issn>2090-6706</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2017</creationdate><recordtype>report</recordtype><recordid>eNqVi70OwiAYABk0sdFuPgCjS-0HbSGMjdHoZqJ7Q1saMQjKT3x9HXwBb7nlDqE1gS0hTVNSILzkFdRAyQxlFAQUjANboDyEO3xhlDHgGarP3k0u2RFftHUyei0Nbr1XIeI2BDdoGdWI3zre8Kn3KWqr-xWaT9IElf-8RJvD_ro7Fk_vXum7dg8dBmWMtMql0BEhKgAhal79kX4A2Nk9CQ</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Mathur, Kanupriya</creator><creator>Saini, Aditya</creator><creator>Ellenbogen, Kenneth A</creator><creator>Shepard, Richard K</creator><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Profound Sinoatrial Arrest Associated with Ibrutinib</title><author>Mathur, Kanupriya ; Saini, Aditya ; Ellenbogen, Kenneth A ; Shepard, Richard K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_19930099473</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Mathur, Kanupriya</creatorcontrib><creatorcontrib>Saini, Aditya</creatorcontrib><creatorcontrib>Ellenbogen, Kenneth A</creatorcontrib><creatorcontrib>Shepard, Richard K</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mathur, Kanupriya</au><au>Saini, Aditya</au><au>Ellenbogen, Kenneth A</au><au>Shepard, Richard K</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Profound Sinoatrial Arrest Associated with Ibrutinib</atitle><jtitle>Case reports in oncological medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><spage>7304021</spage><epage>7304021</epage><pages>7304021-7304021</pages><issn>2090-6706</issn><abstract>BACKGROUNDIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertension in multiple studies. Other forms of cardiac toxicities have also been reported in isolated case reports. Bradycardia and asystole have not been associated with ibrutinib use in the past. CASE REPORTWe present a case of a 76-year-old female with no prior cardiac history, who initiated treatment with ibrutinib for relapsing mantle cell lymphoma and was noted to have symptomatic bradycardia, greater than 20 second long pauses on her cardiac monitor requiring placement of a permanent pacemaker. CONCLUSIONThis is the first case associating bradycardia and asystole with tyrosine kinase inhibitor use. Irreversible inhibition of certain cardioprotective tyrosine kinases has been a growing topic of research in oncology therapeutics.</abstract><doi>10.1155/2017/7304021</doi></addata></record>
fulltext fulltext
identifier ISSN: 2090-6706
ispartof Case reports in oncological medicine, 2017, Vol.2017, p.7304021-7304021
issn 2090-6706
language eng
recordid cdi_proquest_miscellaneous_1993009947
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
title Profound Sinoatrial Arrest Associated with Ibrutinib
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A57%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Profound%20Sinoatrial%20Arrest%20Associated%20with%20Ibrutinib&rft.jtitle=Case%20reports%20in%20oncological%20medicine&rft.au=Mathur,%20Kanupriya&rft.date=2017-01-01&rft.volume=2017&rft.spage=7304021&rft.epage=7304021&rft.pages=7304021-7304021&rft.issn=2090-6706&rft_id=info:doi/10.1155/2017/7304021&rft_dat=%3Cproquest%3E1993009947%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993009947&rft_id=info:pmid/&rfr_iscdi=true